News NICE says 'no' to Roche's Perjeta after breast cancer surger... NICE consulting on first draft decision
News J&J's Tremfya gets funding in Germany and UK Johnson & Johnson’s psoriasis drug Tremfya has been given the green light for funding by cost-effectiveness bodies in the UK and Germany.
Views & Analysis Who should pay for HTA? Part of the drive for strengthening EU cooperation on health technology assessment (HTA) is to tackle duplication of work
News Lung cancer drug Keytruda to become routinely available on N... NICE has given the green light for lung cancer drug Keytruda to be used as a routine treatment for certain patients in England.
News Pfizer will have to cut price of AML drug Mylotarg after NIC... NICE blocks access to 65% of patients on cost grounds
News NICE asks EUSA pharma to drop price of neuroblastoma drug NICE calls for price cut before possible CDF funding
News Hengrui gets world-first okay for platelet drug hetrombopag Hengrui's oral TPO agonist, hetrombopag, is the first in the class to be approved for thrombocytopenia caused by chemotherapy for solid tumours.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
